Uitgebreid zoeken

Mathieu Lamy bekleedt de functie van Chief Operating Officer & Executive Vice President bij Intact Financial Corp. Hij is tevens Senior Vice President-Claims bij Claims At Intact Insurance. Daarvoor was hij Chief Information Officer & Senior Vice President bij IntAct Labs LLC, Executive Vice President-Operations bij AXA Life Insurance (Canada) en Executive Vice President van AXA Canada, Inc. De heer Lamy behaalde een bachelordiploma aan de Universit Laval.

Mr. Mathieu Bonnet is a Chairman at E6 SAS, a Chief Executive Officer & Director at Allego BV, a Chief Executive Officer & Director at Allego NV, a Chief Executive Officer at Allego BV (New) and a President at Spartan Acquisition Corp.
III.
He is on the Board of Directors at Allego BV and Allego NV.
Mr. Bonnet was previously employed as a Chief Executive Officer by Compagnie Nationale du Rhône.
He received his undergraduate degree from Ecole Polytechnique, a graduate degree from École Nationale Supérieure des Mines de Paris and a graduate degree from Université Catholique de Louvain.

Dr. Mathieu Simon is Voorzitter bij Epsilen Bio SRL, Voorzitter bij Idorsia Ltd., Onafhankelijk Bestuurder bij Asarina Pharma AB, Onafhankelijk Bestuurder bij Vaximm AG, Voorzitter bij Idorsia Pharmaceuticals Ltd., Chief Executive Officer bij Cellectis Therapeutics en Onafhankelijk Bestuurder bij LNC Therapeutics SA. Hij zetelt in de Raad van Bestuur van Lysogene SA, Asarina Pharma AB, Affimed NV, Affimed GmbH, Vaximm AG, Messier Maris & Associs SCA en LNC Therapeutics SA. Dr. Simon was voorheen werkzaam als EVP, Chief Operating & Medical Officer bij Cellectis SA, als Vice President-Marketing & Medical Affairs bij Wyeth Pharmaceuticals LLC, als Group VP-Marketing & Clinical Affairs bij Wyeth-Ayerst International, Inc, als Senior Vice President-Global Operations bij Pierre Fabre Mdicament SAS, als Managing Director & Head-Global Pharma bij Pierre Fabre SA, en als Chairman & Chief Executive Officer bij Takara Bio Europe AB. Hij was ook lid van de raad van bestuur van Alliance for Regenerative Medicine, Ectycell SASU en Farmindustria.

Mathieu Bernard Streiff is the founder of American Healthcare Investors LLC, which was founded in 2011.
He held the title of General Counsel & Managing Director at the firm from 2011 to 2019.
Mr. Streiff's current jobs include being a Director at Hawkhill House Ltd.
since 2016, a Director at American Healthcare REIT, Inc. since 2015, a Director at GAHC3 U.K.
Senior Care Holding Ltd., a Director at Coniston Care Centre Ltd.
since 2016, a Director at Orchard St Albans Housing Portfolio Ltd.
since 2015, a Member of the New York State Bar Association, an Executive Vice President at Griffin-American Healthcare REIT Sub-Advisor, LLC since 2012, and an Executive Vice President at Griffin-American Healthcare REIT III Advisor LLC since 2012.
Mr. Streiff's former jobs include being a Director at Trilogy Investors LLC, Executive Vice President & General Counsel at Grubb & Ellis Co. from 2010 to 2011, Executive Vice President & General Counsel at Griffin-American Healthcare REIT II, Inc. from 2012 to 2014, Executive Vice President & General Counsel at Griffin-American Healthcare REIT III, Inc. from 2013 to 2021, an Associate at Latham & Watkins LLP from 2002 to 2006, Secretary, Executive VP & General Counsel at Grubb & Ellis Realty Investors LLC in 2011, and Executive Vice President at Griffin American Healthcare Reit Advisor LLC from 2011 to 2014.
Mr. Streiff's education includes an undergraduate degree from the University of California, Berkeley and a graduate degree from Columbia Law School.

Momenteel bekleedt Mathieu Vrijsen de functie van Voorzitter-Raad van Commissarissen bij Casco Phil, Voorzitter-Raad van Commissarissen bij Broadview Holding BV en Voorzitter-Raad van Commissarissen bij Corbion NV. De heer Vrijsen is tevens lid van de Raad van Bestuur van de Zwitsers-Amerikaanse Kamer van Koophandel, de Europese Vereniging voor Bio-industrieën, Desso BV en Joma Sport BVBA en lid van het Uitvoerend Comité van het International Institute for Management Development. In zijn vorige carrière bekleedde hij de positie van Senior Vice President-Operations & Engineering bij E.I. du Pont de Nemours & Co.

De heer Mathieu O. Floreani is Voorzitter van de Raad van Bestuur & CEO bij Synlab AG, Co-Managing Director bij LS Medizin Service GmbH, Group Chief Executive Officer bij SYNLAB International GmbH en Co-Managing Director bij Medizinisches Versorgungszentrum SYNLAB Leverkusen GmbH. Hij is lid van de Raad van Bestuur bij Synlab Diagnsticos Globales SA, ALcontrol Group Ltd., Labco UK Group Ltd. en SYNLAB Ltd. De heer Floreani was voorheen werkzaam als President, Chief Executive Officer & Director bij DHL Global Forwarding North America en als Managing Director bij SYNLAB Medizinisches Versorgungszentrum Stuttgart GmbH.

Veronique Lamy has worked as the Director of Human Resources at Eurogerm SA since 1989.

Dr. Thomas Lamy is a Director & Vice President at Biosynex SA, a Chairman at A.J.T.
Financière SAS, a Chief Executive Officer & Director at Biosynex Premier SA, a Chief Executive Officer & Director at Biosynex Swiss SA and a Sales Manager at PBS Orgenics.
He is on the Board of Directors at Biosynex SA, Biosynex Premier SA and Biosynex Swiss SA. Dr. Lamy was previously employed as a Chief Executive Officer by Dectra Pharm SAS and a Chairman & Managing Director by All Diag.
He also served on the board at Theradiag SA. He received his MBA from École des Hautes Études Commerciales de Paris and a doctorate degree from the Institut National Polytechnique de Lorraine.

Christophe Lamy has been the General Manager at Envea SA since 2001.

Tiphanie Lamy is currently the Deputy Managing Director at FLCP & Associés SASU and FLCP & Associes Invest SAS.
She is also a Member-Supervisory Board at Focus Entertainment SA. Previously, she worked as a Director at Tuvalu Media Netherlands BV.

Guillaume Lamy has worked as a Co-Chief Executive Officer at Production la Prade since 2020.

Esdra Lamy currently works at Airline Passenger Experience Association, Inc., as Director.

Emilie Lamy has worked as a Director at Prestige Motor Holdings SA since 2015.

Laurence Lamy currently works as a Manager of Corporate Communications at Mersen SA.

Yasemin Lamy joined British International Investment as Deputy CIO in August 2018.
She is responsible for the Catalyst Strategies, a portfolio aimed at transformational, system-level impact and innovation across its target geographies of Africa and South Asia.
Prior to British International Investment, she spent three years building two new portfolios for Omidyar Network: one portfolio to develop empowering digital identity technologies and one portfolio to establish a trendspotting capability.
Previously, she worked across several different roles within capital markets at J.P.
Morgan, starting out in fund-linked derivatives and then as a credit derivatives analyst, before building and leading the impact investment platform for the firm.
Yasemin has published widely and provided expert advice to the OECD, World Economic Forum and others.
She holds a Masters in Financial Mathematics from King’s College, London and a Bachelor in Mathematics and Philosophy from the University of Pennsylvania.

Donzé Aurélia Lamy worked as a Portfolio Manager at Edmond de Rothschild Asset Management (Suisse) SA from 2009 to 2015.

Mr. Arnaud-Guilhem Lamy is a Head of Euro Aggregate Bond Management Strategies at BNP Paribas Asset Management Europe SAS.
He is responsible for euro-aggregate's bond management strategies and is also an expert in socially responsible investment (SRI) for bond management.
Prior to joining BNP Paribas Asset Management in 2010, he was Eurobond Portfolio Manager at Fortis Investments in London (2007-2010), responsible for ABS and covered bonds.
He was a credit analyst at Société Générale Asset Management (2005-2007), after starting his career at Crédit Foncier de France in 2001 as a securitisation specialist.
He graduated in Finance and Economics from the Ecole Nationale de la Statistique et de l'Administration Economique (ENSAE, France, 2001).
He also holds a Master's degree in Applied Mathematics from Dauphine University (Paris, France, 1999).

Guillaume Lamy currently works at Menguy's SA, as Co-Chief Executive Officer, Les Fromageries Occitanes SAS, as Marketing Director, and Sphere Production SA, as Managing Director.

Caroline Lamy is currently working as the Co-Head of Equity Management at Crédit Mutuel Asset Management SA since 2021.
Previously, she worked as an Analyst at ING Belgium SA (France) in 2001.

Dr. Francis M.
Lamy is Chief Technology Officer at XR Ventures LLC.
Dr. Francis Lamy is Chief Technology Officer at XR Ventures LLC and Chief Technology Officer X-Rite.
Prior to joining XR Venture, he served as Executive Vice President and Chief Technology Officer for GretagMacbeth AG (Amazys Holding AG) from 2002-2006.
Prior to GretagMacbeth in 1999,he was the founder and president of Dalim, a workflow software company for the graphic arts markets, which he conducted from inception to world scale deployment.
Dr. Lamy holds a PhD in physics from the University Of Strasbourg, France.
Earlier in his career, in his post-doc days, he was assistant professor of Solid State Physics at the University of Strasbourg, and consultant to the French Ministry of Industry in innovation matters.

Teresa Lamy is currently a Chartered Fellow at the Chartered Institute of Personnel & Development.
She previously worked as a Principal at Barclays PLC and Jersey Post International Ltd.

Damien Lamy has worked as a Director at Euro Heat Pipes SA since 2008 and is currently employed there.
He is also a Director at KapCare SA, where he currently works.

Alina Lamy is a Senior Analyst at Morningstar, Inc. (Research).
She completed her undergraduate degree at Illinois Institute of Technology.

Olivier Lamy is currently a Director at Pobi Industrie SA, Pobi Charpentes SA, Perform Habitat SAS, La Barrade SNC, and AST Services SAS.
He previously worked as a Director-Administrative & Finance at A.S.T.
Groupe SA from 2013 to 2016 and as a Senior Manager at Arthur Andersen & Cia from 2001 to 2002.
Mr. Lamy obtained his undergraduate degree from ESCP Europe Campus Paris in 1998 and Burgundy School of Business in 1998.

Marc Lamy has held positions as an Independent Non-Executive Director at Alliances Developpement Immobilier SA and as a Founding Member at Institut Français Des Administrateurs.

Bernard Lamy currently works as a Director at Sarcelles Energie SA.

David Lamy currently works at Tradecowall SCRL, as Chief Executive Officer from 2016, Recynam NV, as Managing Director from 2010, and Recyhoc NV, as Director from 2016.

Kenneth S.
Lamy is the founder of The Lamy Group Ltd.
He is currently working as a Director at the National Association of Real Estate Cos.

Jean-Lucien Lamy is currently the Chief Executive Officer at FCI USA LLC.
Prior to this, he worked as a Director at Aliaxis SA.

Pascal Lamy is currently the Director at Thomson Reuters Founders Share Co., Ltd., the Director at Centre on Regulation in Europe, a Professor at China Europe International Business School, and the President-Emeritus at Jacques Delors Institute.
He was formerly the Director General at the World Trade Organization.

Lucienne Lamy currently works at Cooperative Immobilière de Bretagne, as Director.

Patrick Lamy's career history includes current and former positions as well as education.
Currently, he is the Senior Vice President-Commercial Strategy at Akero Therapeutics, Inc. Previously, he worked at Gilead Sciences, Inc. as the Head-Commercial Strategy & Banking from 2008 to 2018, and at Iovance Biotherapeutics, Inc. as the Vice President-Commercial from 2018 to 2021.
In terms of education, Mr. Lamy holds an MBA from the University of California, Berkeley, and an undergraduate degree from the University of California San Diego.

Mr. Gérard Lamy is a Director-Research at Wendel SA and a Member at The French Society of Financial Analysts.
He received his undergraduate degree from École des Hautes Études Commerciales de Paris.

François Lamy currently works as a Director for the Association Française contre les Myopathies.